Efficacy of indomethacin in in vitro fertilisation treatment in the modified natural cycle.

Efficacy of indomethacin in in the prevention of premature ovulation in in vitro fertilisation treatment in a with a GnRH-antagonist modified natural cycle.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25697

Enrollment

120

Registered

2007-02-13

Start date

2005-12-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

indomethacin

Interventions

Use of indomethacin (Indocid®) 50 mg versus placebo during IVF-treatment in the modified natural cycle. Dosage scheme: three times a day, starting on the day of ovulation triggering and ending on th

Eligibility

Inclusion criteria

Inclusion criteria: 1. Indication for IVF or ICSI treatment; 2. Age 18 up to 37 years; 3. Ovulatory cycle of 26-35 days.

Exclusion criteria

Exclusion criteria: 1. Prior IVF or ICSI treatment unless the last treatment was succesfull; 2. Ovarian cysts disabling adequate sonographic assessment of the ovaries; 3. Contra-indications for indomethacin, such as asthma or prior gastro-intestinal ulcer.

Design outcomes

Primary

Measure	Time frame
Number/percentage of patients per study group that have one or more ovulations prior to follicle aspiration.	—

Secondary

Measure	Time frame
Number/percentage of patients per study group that achieve an ongoing pregnancy (defined as an intact intra-uterine pregnancy at 12 weeks gestation).	—

Contacts

Public ContactM.L. Haadsma

University Medical Center Groningen Department of Obstetrics and Gynaecology

m.l.haadsma@og.umcg.nl+31 50-3616161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)